Patent US5631015A successfully refreshed from Google Patents.
US5631015A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Liquid absorbable copolymers for parenteral applications
Assignee: Ethicon Inc
•
Filing: 1996-05-20
•
Granted: 1997-05-20
•
Expires: 2016-05-20
Abstract
Abstract A sustained release parenteral composition comprising an admixture of at least one drug to be delivered in a therapeutically effective amount and a bioabsorbable lactone polymer containing one or more lactone monomers that is a liquid at body temperature, provided in an amount effective to sustain or extend the release rate of the drug and a method for administering said composition to an animal.
Inventors
- 👤 Rao S. Bezwada
- 👤 Stephen C. Arnold
- 👤 Shalaby W. Shalaby
- 👤 Bernard L. Williams
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 03:55
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61K47/00; A61K47/30; A61K47/34
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
117 words
A liquid parenteral composition for injection subcutaneously or intramuscularly into animals of at least one drug consisting essentially of an admixture of at least one drug to be delivered in a therapeutically effective amount; and a bioabsorbable lactone copolymer composed of two lactone monomers selected from the group consisting of L-lactide, 1,4-dioxanone, ε-caprolactone, 1,5-dioxepan-2-one and trimethylene carbonate said copolymer being a liquid at body temperature, provided in an amount effective to sustain or extend the release rate of the drug, wherein the inherent viscosity of the copolymer is between about 0.05 dL/g and about 0.8 dL/g as determined in a 0.1 g/dL solution of hexafluoroisopropanol at 25° C. and the lactone copolymer contains substantially no unreacted monomer.
Claim 2
Dependent Claim
117 words
A liquid parenteral composition for injection subcutaneously or intramuscularly into animals of at least one drug consisting essentially of an admixture of at least one drug to be delivered in a therapeutically effective amount; and a bioabsorbable lactone copolymer composed of two lactone monomers selected from the group consisting of L-lactide, 1,4-dioxanone, ε-caprolactone, 1,5-dioxepan-2-one and trimethylene carbonate said copolymer being a liquid at body temperature, provided in an amount effective to sustain or extend the release rate of the drug, wherein the inherent viscosity of the copolymer is between about 0.05 dL/g and about 0.8 dL/g as determined in a 0.1 g/dL solution of hexafluoroisopropanol at 25° C. and the lactone copolymer contains substantially no unreacted monomer.
Claim 3
Dependent Claim
14 words
The parenteral composition of claim 1 wherein the copolymers are liquids at 25° C.
Claim 4
Dependent Claim
24 words
The parenteral composition of claim 1 wherein the copolymer is a copolymer selected from the group consisting of poly(lactide-co-ε-caprolactone), poly(lactide-co-p-dioxanone), poly(lactide-co-1,5-dioxepan-2-one), poly(ε-caprolactone-co-p-dioxanone) and poly(1,5-dioxepan-2-one-co-p-dioxanone).
Claim 5
Independent Claim
123 words
A method for parenterally administering a drug subcutaneously or intramuscularly into animals consisting essentially of injecting a liquid composition consisting essentially of an admixture of a therapeutic amount of at least one drug and a bioabsorbable lactone copolymer composed of two lactone monomers selected from the group consisting of L-lactide, 1,4-dioxanone, ε-caprolactone, 1,5-dioxepan-2-one and trimethylene carbonate said copolymer being a liquid at body temperature, provided in an amount effective to sustain or extend the release rate of the drug, wherein the inherent viscosity of the copolymer is between about 0.05 dL/g and about 0.8 dL/g as determined in a 0.1 g/dL solution of hexafluoroisopropanol at 25° C., the lactone copolymer contains substantially no unreacted monomer and the composition remains a liquid after administration.
Claim 6
Independent Claim
123 words
A method for parenterally administering a drug subcutaneously or intramuscularly into animals consisting essentially of injecting a liquid composition consisting essentially of an admixture of a therapeutic amount of at least one drug and a bioabsorbable lactone copolymer composed of two lactone monomers selected from the group consisting of L-lactide, 1,4-dioxanone, ε-caprolactone, 1,5-dioxepan-2-one and trimethylene carbonate said copolymer being a liquid at body temperature, provided in an amount effective to sustain or extend the release rate of the drug, wherein the inherent viscosity of the copolymer is between about 0.05 dL/g and about 0.8 dL/g as determined in a 0.1 g/dL solution of hexafluoroisopropanol at 25° C., the lactone copolymer contains substantially no unreacted monomer and the composition remains a liquid after administration.
Claim 7
Dependent Claim
13 words
The method of claim 4 wherein the copolymers are liquids at 25° C.
Claim 8
Dependent Claim
23 words
The method of claim 4 wherein the polymer is a copolymer selected from the group consisting of poly(lactide-co-ε-caprolactone), poly(lactide-co-p-dioxanone), poly(lactide-co-1,5-dioxepan-2-one), poly(ε-caprolactone-co-p-dioxanone) and poly(1,5-dioxepan-2-one-co-p-dioxanone).
References Cited (Backward Citations)
FR2390962A1
Cited
US4526938A
Cited
US4818542A
Cited
US4803075A
Cited
WO1990003768A1
Cited
US5278201A
Cited
US5278202A
Cited
WO1990005522A1
Cited
US5077049A
Cited
DE4235312A1
Cited
US5322925A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-05-19 | 2000-11-18 | 2001-05-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-05-19 | 2004-11-18 | 2005-05-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-05-19 | 2008-11-18 | 2009-05-20 | $7700.00 | Window Closed / Lapsed |